Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
IP Group plc ( (GB:IPO) ) has shared an announcement.
IP Group’s portfolio company, Istesso, announced the results of its Phase 2b study for leramistat, a potential rheumatoid arthritis treatment. Although the study did not meet its primary endpoint, significant improvements were observed in secondary outcomes like bone protection and reduction in disability and fatigue. These findings support further exploration of leramistat’s potential as a treatment for RA and other chronic conditions, highlighting its novel mechanism of action. Istesso plans additional studies and is well-funded for future research, with IP Group holding a significant stake in the company.
More about IP Group plc
IP Group plc is a UK-based early-stage science investor, focusing on deeptech, life sciences, and cleantech. The company supports innovative businesses emerging from leading universities and research institutions, with investments in companies like Oxford Nanopore Technologies. Istesso, a portfolio company of IP Group, focuses on chronic disease treatments aimed at repairing damage rather than merely controlling symptoms.
YTD Price Performance: -9.46%
Average Trading Volume: 3,274,347
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £470.5M
Learn more about IPO stock on TipRanks’ Stock Analysis page.
